ClinicalTrials.gg
CompletedNCT07078630IN-FORMUpdated Aug 21, 2025

Modulation of hepcidIN With Co-supplementation of Iron and FORMulated Curcumin in Recreational Athletes

An interventional study of Placebo and HydroCurc® in Iron Supplementation and Gastrointestinal Health and Iron Deficiency, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Oct 2023, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.

Enrollment
18th of 19
10 · median 50
Started
2023
with 1 other
No phase
11 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
2 of 22
University of Westminster

Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 11 with no phase, and was the 22nd registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Iron Deficiencies with a site in United Kingdom, or all of them as a file.
02

Study summary

Iron deficiency and iron deficiency anaemia are common among endurance athletes partly due to a repeated post-exercise elevation of hepcidin, a hormone limiting iron entry through the intestine. Oral iron supplementation also causes stimulation of hepcidin that adds on to the exercise-intrinsic stimulation of this hormone further reducing iron absorption. Both oral ferrous iron therapy and performance running are known to cause undesired gastrointestinal symptoms. Curcumin, a polyphenol from turmeric, has been previously shown to reduce hepcidin levels in resting individuals and to protect the gastrointestinal (GI) function but its effect on active individuals supplementing with iron remains unclarified.

The objective of this research study is to learn about the effects of a formulated curcumin (HydroCurc®) on intestinal health and regulation mechanisms of body iron levels in recreationally active athletes supplementing with iron.

The main questions to answer are:

Does HydroCurc® influence iron regulatory mechanisms in resting conditions? Does HydroCurc® influence iron regulatory mechanisms in post-exercise conditions? Does HydroCurc® alleviate iron supplementation- and exercise-related gastrointestinal adverse events

Researchers will compare HydroCurc® to a placebo (a look-alike substance that contains no drug) to see if there are any significant changes.

Participants will:

  • Perform a fitness test
  • Take iron and HydroCurc for seven days
  • Complete questionnaires on their gastrointestinal health
  • Complete anthropometric testing
  • Undergo blood sampling
Read the detailed description

Intervention study with two treatment groups in a randomised, double-blinded, placebo-controlled, crossover design.

Healthy recreationally active athletes will perform a VO2 max test to determine their aerobic capacity. A blood sample will be taken prior to the test as baseline measurement. Following treatment with iron plus either HydroCurc or a matched placebo for a week, participants will run on a treadmill for one hour at 70% of their maximal capacity. Blood samples will be collected before, immediately after, one hour post- and three hours post-exercise. Gastrointestinal symptoms will be assessed via validated questionnaires during the supplementation period and the experimental visits. All participants will observe a minimum of a two-week washout period. All participants will attend visits fasting for a minimum of four hours.

03

Conditions studied

  • Iron Supplementation and Gastrointestinal Health
  • Iron Deficiency

Keywords

  • Iron
  • Ferrous sulphate
  • Curcumin
  • IFABP
  • Ferritin
  • Interleukin-6
  • Hepcidin
  • Iron deficiency
  • Anaemia
  • Inflammation
  • Oxidative stress
  • Supplement
  • Gastrointestinal symptoms
  • Nutraceutical
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (18-40 years) endurance male \& female runners.
  • All participants will be accustomed to exercising at least 150 minutes per week, meeting the minimum NHS exercise recommendation.
  • Participants will be fit enough to run for 60 minutes on a treadmill at 70% of their V̇O2max. To that end, participants will undergo a fitness test in the screening visit.

Exclusion criteria

Exclusion Criteria:

  • \<18 years or >40 years
  • Those with deficient/excess/abnormal iron levels according to UK guidelines \&/or haemochromatosis
  • Any allergies/health issues related to items being ingested.
  • Any illnesses or those on medication
  • Those on iron or curcumin supplements
  • Any pregnant or lactating women
  • Any women who are trying to conceive
  • Any gastrointestinal disorders
  • Any eating disorders
  • Any abnormal blood pressure levels
  • Consumption of >14 units of alcohol/week
  • Devices such as pacemakers
  • Smokers
  • Renal disorders
  • Dieters

These criteria will be self-reported.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Placebo comparator
    Ferrous iron + placebo

    * Dried ferrous sulphate tablet, 200mg providing 65 mg of elemental iron (Remedy Healthcare, UK). * Placebo capsule containing maltodextrin and a food grade dye (yellow 5 or E102) (Fast Colours LLP, Huddersfield, UK)

    Dietary Supplement: Placebo · Dietary Supplement: Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron

  • Active comparator
    Ferrous iron + HydroCurc

    * Dried ferrous sulphate, 200mg tablet providing 65 mg of elemental iron (Remedy Healthcare, UK). * HydroCurc (Gencor Pacific Limited, Lantau Island, Hong Kong), 500 mg capsule containing not less than 90% 115 curcuminoids (85% curcumin), formulated in 10% LipiSperse® (Pharmako Biotechnologies Pty Ltd, 116 Sydney, Australia), a delivery system comprising a proprietary mixture of surfactants, polar lipids 117 and solvents.

    Dietary Supplement: HydroCurc® · Dietary Supplement: Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron

Interventions

  • Dietary supplementPlacebo

    Participants instructed to intake the placebo capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.

  • Dietary supplementHydroCurc®

    Participants instructed to intake the HydroCurc® capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.

  • Dietary supplementFerrous sulfateStudies of Ferrous sulfateFerrous sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants instructed to intake the ferrous sulphate tablet along with the HydroCurc® or the placebo together, preferably and separated from food, tea or coffee, at the same time of the day.

06

What researchers measure

Primary outcomes

  1. Concentration of iron absorption regulatory hormone in athletes supplementing with ferrous iron in resting conditions

    Hepcidin, ng/mL

    Time frame: Hepcidin measured 1 day post supplementation

  2. Exercise-associated hepcidin concentration in athletes supplementing with ferrous iron

    Hepcidin, ng/mL

    Time frame: Hepcidin measured 180 minutes post-exercise

  3. Ferrous iron-associated iron status in athletes

    Ferritin, ng/mL

    Time frame: Ferritin measured 1 day post supplementation

  4. Change of exercise-associated inflammation in ferrous iron supplemented athletes

    Interleukin-6, pg/mL

    Time frame: Interleukin-6 measured 0- and 60-minutes post-exercise

Secondary outcomes

  1. Exercise-associated intestinal damage in ferrous iron supplemented athletes

    Intestinal Fatty Acid Binding Protein (IFABP), pg/mL

    Time frame: IFABP measured 0- and 60-minutes post-exercise

  2. Incidence and frequency of ferrous iron associated-gastrointestinal symptoms

    Subjective analysis via Oral Iron Supplement Questionnaire

    Time frame: Gastrointestinal symptoms analysed daily throughout the supplementation period (seven continuous days)

  3. Number of participants supplementing with ferrous iron and reporting exercise-associated gastrointestinal symptoms

    Subjective analysis via gastrointestinal symptom questionnaire

    Time frame: Gastrointestinal symptoms measured 30 minutes after the commencement of the exercise, 0-, 60- and 180- minutes post-exercise.

07

Study locations

1 site
  • University of Westminster London
    London, Greater London W1W6UW, United Kingdom
08

References and documents

Publications

  • Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015 Feb 20;10(2):e0117383. doi: 10.1371/journal.pone.0117383. eCollection 2015. PubMed 25700159 ↗
  • Szymanski MC, Gillum TL, Gould LM, Morin DS, Kuennen MR. Short-term dietary curcumin supplementation reduces gastrointestinal barrier damage and physiological strain responses during exertional heat stress. J Appl Physiol (1985). 2018 Feb 1;124(2):330-340. doi: 10.1152/japplphysiol.00515.2017. Epub 2017 Sep 21. PubMed 28935827 ↗
  • Peters HP, Bos M, Seebregts L, Akkermans LM, van Berge Henegouwen GP, Bol E, Mosterd WL, de Vries WR. Gastrointestinal symptoms in long-distance runners, cyclists, and triathletes: prevalence, medication, and etiology. Am J Gastroenterol. 1999 Jun;94(6):1570-81. doi: 10.1111/j.1572-0241.1999.01147.x. PubMed 10364027 ↗
  • Ishibashi A, Maeda N, Kamei A, Goto K. Iron Supplementation during Three Consecutive Days of Endurance Training Augmented Hepcidin Levels. Nutrients. 2017 Jul 30;9(8):820. doi: 10.3390/nu9080820. PubMed 28758951 ↗
  • Laine F, Laviolle B, Bardou-Jacquet E, Fatih N, Jezequel C, Collet N, Ropert M, Morcet J, Hamon C, Reymann JM, Loreal O. Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study. Fundam Clin Pharmacol. 2017 Oct;31(5):567-573. doi: 10.1111/fcp.12288. Epub 2017 May 7. PubMed 28370178 ↗
  • Larsuphrom P, Latunde-Dada GO. Association of Serum Hepcidin Levels with Aerobic and Resistance Exercise: A Systematic Review. Nutrients. 2021 Jan 27;13(2):393. doi: 10.3390/nu13020393. PubMed 33513924 ↗
  • Keller K, Friedrich O, Treiber J, Quermann A, Friedmann-Bette B. Iron deficiency in athletes: Prevalence and impact on VO2 peak. Nutrition. 2024 Oct;126:112516. doi: 10.1016/j.nut.2024.112516. Epub 2024 Jun 10. PubMed 39002373 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jan 2024, 3 months.

Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 3 months is below that.

Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 22, 2025
StartActual
Oct 5, 2023
Primary completionActual
Jan 24, 2024
CompletionActual
Jan 24, 2024
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07078630
Lead sponsor
University of Westminster
Collaborators
Pharmako Biotechnologies Pty Ltd
Responsible party
Mohammed Gulrez Zariwala (Professor of Translational Physiology, University of Westminster) — Principal investigator
First posted
Jul 22, 2025
Start date
Oct 5, 2023
Primary completion
Jan 24, 2024
Completion
Jan 24, 2024
Last update
Aug 21, 2025

Study contacts

Mohammed G Zariwala, PhD
principal investigator · University of Westminster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion